Results 91 to 100 of about 311 (111)

A Randomized, Cross-Over Study Investigating the Comparability of Somatrogon-Ghla in 2 Different Drug Product Presentations

Clinical Pharmacology in Drug Development
Abstract Somatrogon‐ghla is a long‐acting, recombinant human growth hormone approved for the treatment of pediatric patients with growth hormone deficiency. Forty‐nine healthy, adult males were enrolled in a randomized, crossover study to compare somatrogon exposure after subcutaneous doses administered using a frozen vial presentation or a prefilled ...
Michael P Wajnrajch
exaly   +2 more sources

Somatrogon

Reactions Weekly
core   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Somatrogon

Reactions Weekly, 2020
  +8 more sources

Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products

Expert Review of Endocrinology & Metabolism, 2023
Somatrogon (NGENLA™) is a long-acting GH (LAGH) formulation that was approved in Canada in October 2021 for the treatment of pediatric growth hormone deficiency (GHD). Somatrogon has also received approval in Australia, Japan, the European Union, the USA, and the UK.
Eric P, Velazquez, Bradley S, Miller, Kevin C J, Yuen   +2 more
openaire   +2 more sources

Somatrogon

Reactions Weekly, 2019
  +7 more sources

Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-Analysis [PDF]

Advances in Therapy
Lasse de Fries Jensen, Vasileios Antavalis, Michael Hojby Rasmussen   +2 more
exaly   +2 more sources

Somatrogon-ghla

American Journal of Health-System Pharmacy, 2023
openaire   +2 more sources

Is Somatrogon different? 6-month clinical outcomes and follow-up data in Turkish children transitioned from Somatropin to Somatrogon

Growth Hormone & IGF Research
Long-acting growth hormone (GH) formulations have been developed to reduce treatment burden and improve adherence in children with growth hormone deficiency (GHD). Somatrogon is a long-acting recombinant GH analog designed for once-weekly administration and has demonstrated comparable efficacy to daily somatropin in clinical trials. However, real-world
Nurgul, Atas, Rabia Deniz, Kılçık, Fatoş Çirkin, Melik, Murat, Karaoğlan, Mehmet, Keskin, Serpil, Albayrak   +5 more
openaire   +2 more sources

Somatrogon

Reactions Weekly, 2021
openaire   +1 more source

Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injections vs. Daily Growth Hormone Injection for Treating Paediatric Growth Hormone Deficiency in Ireland

Journal of Medical Economics, 2023
Jane Loftus, Simone Rivolo, Balázs Peter   +2 more
exaly